박수경 등. 아시아 의사들의 바이오시밀러에 대한 관점
The Korean Journal of Gastroenterology members in 2013. The survey showed that a minority of IBD specialists were aware and confident about the benefits and issues of biosimilars. 3 In 2015, an ECCO survey was conducted to examine the evolution of IBD specialists' views after 2 years.
The opinion of IBD experts on the use of biosimilar monoclonal antibodies has changed dramatically toward a more favorable and confident position. 4 These might be because of the increased knowledge from postgraduate education and published evidence from clinical practice.
Although the incidence of IBD in Asia has increased rapidly in recent years [5] [6] [7] [8] and the first infliximab biosimilar, CT-P13 (Remsima ® ; Celltrion Inc.), was produced by a Korean biopharmaceutical company and licensed for the Korean market in 2012, the current knowledge and viewpoints regarding biosimilars among physicians in Asia is unknown. Therefore, this study conducted a multinational survey to assess the awareness of biosimilar mAb among physicians in Asian countries.
SUBJECTS AND METHODS

Study design and data collection
This study adopted the questions used to survey ECCO 
RESULTS
Participant characteristics
Initially, 320 AOCC members were selected randomly and invited to this study. Table 2 ).
General aspects and advantages of biosimilars
In the definition of mAb, the majority of respondents (66.2%) were aware that a biosimilar is a similar product, but not equal to the originator; 27.8% responded that it is a copy of a biological agent, identical to the originator (like a generic), and a further 8% confused a biosimilar with a different anti-tumor necrosis factor (TNF) agent, like adalimumab to infliximab, which was similar to the ECCO members response in 2013 (70%, 19%, and 8%, respectively).
Interestingly, among Asian countries, a higher proportion of physicians in Korea (47.2%) defined a mAb as a copy of a biological agent that was identical to the originator compared to participants from other Asian countries (Japan 4.3%, China 20.6%, and others 0%, p<0.001) (Supplementary Table 2 ).
With regard to the issues or advantages of biosimilar mAb, 19 .9% of respondents estimated that biosimilars had differ- ent activities than the originator, and 38.4% of respondents estimated that these would present a different immunogenicity pattern than the originator, proportions which were similar to the ECCO members' opinions in 2015 (16.9% and 27.1% respectively), but lower than those of the ECCO members in 2013 (43% and 67% respectively) ( Fig. 1 ). On the other hand, a smaller percentage of respondents (77.5%) considered cost saving to be the main advantage of biosimilars compared to 92.4% of ECCO members in 2015 and 89.5%
in 2013 ( Fig. 1 Table 2 ).
When participants were asked, in the case of an IBD patient in prolonged remission under an originator mAb, whether the scheduled therapy should be continued with a biosimilar, 36.4% disagreed citing a lack of disease-specific evidence of interchangeability (72.2% in ECCO 2013 and 39.9% in ECCO 2015); 49.7% agreed but stated that they would provide detailed information to their patient regarding the limited data 
Extrapolation across indications
In the theoretical case of a randomized controlled trial for rheumatology patients showing no differences between a biosimilar and its originator, 39.1% believed the biosimilar should be approved for all indications of the originator (24.2% in ECCO 2013 and 50.8% in ECCO 2015). In the case of IBD, in which a theoretical randomized controlled trial showed no differences between a biosimilar and the originator in CD, 52.3% would use it only in CD (53% in ECCO 2013 and 25% in ECCO 2015); 21.2% would also use the biosimilar in UC (16% in ECCO 2013 and 31% in ECCO 2015), and 23.8%
would still wait for more evidence for both CD and UC (30% in ECCO 2013 and 8.6% in ECCO 2015) ( Fig. 3 ).
For the actions required of medical societies, 45.7% thought that medical societies should promote information on in ECCO 2013 and 52% in ECCO 2015).
Confidence regarding the use of biosimilars
Finally, when asked whether they would feel confident in prescribing biosimilars to their participants, only 6.0% felt confident in the use of biosimilars compared to 5% and 28.8%
of ECCO members in 2013 and 2015, respectively ( Fig. 4 ).
When the association between the degree of confidence and access to biosimilars was analyzed, participants who had never prescribed these agents or participants from countries in which these agents were unavailable showed a higher proportion of little or no confidence (Spearman's r=-0.31, p<0.001) ( Fig. 5 ).
DISCUSSION
The first infliximab biosimilar was introduced to the The proportion of physicians in Korea who prescribed biosimilars for more than 2 years was 41.5% in Korea, 20.6%
in China, and less than 5% in other Asian countries (Supplementary Table 2 ). In addition, a proportion of Asian gastroenterologists still had misconceptions regarding biosimilars, viewing them as generic copies of the original biologic agents. Compared to ECCO members, a lower percentage of respondents considered lower prices as the main advantage of biosimilars in this study. An explanation may be that because Asian governments are using pharmaceutical pricing strategies to contain rising healthcare costs, there is a relatively small price difference between the originators and biosimilars. 9 In particular, the single price system is applied in Korea so that the prices of the innovator drug and its alternative have become similar. 10 In Asia, although the concerns of immunogenicity were not serious, they were higher than ECCO 2015, and the proportion of respondents who thought that each biosimilar should carry a distinct INN was higher than ECCO 2015.
In the present survey, there were more concerns regarding 13 In Western countries, clinical evidence regarding biosimilars is derived from cohort studies on IBD patients, both in CD and UC. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Although the extrapolation for use in other indications is essential to keep the cost of biosimilars competitive, well-designed, prospective randomized non-inferiority trials for efficacy and safety, as well as immunogenicity and interchangeability will be needed before clinicians confidently integrate biosimilars into IBD treatment.
In addition, as the physician's accessibility and experience 
How would you best define a monoclonal antibodies (mAb) biosimilar?
1) A biosimilar is similar, but not equal to the originator 2) A biosimilar is a copy of a biological agent, identical to the originator (like a generic)
3) A biosimilar is a different anti-TNF agent, like adalimumab and infliximab 3. What could be issues or advantages of a mAb biosimilar? (more than one answer possible) 1) They can work differently from the originator 2) They can have a different immunogenicity pattern than the originator 3) Switching from originator to one or more of its biosimilars may boost immunogenicity 4) The patients' rights to know which drug is given to them may be challenged 5) They will be less expensive than the originator 6) There will be more extensive indications than for the originator 2) There should be joint position statements by physicians and patients' associations to regulators
3) This is a matter for expert physicians and regulatory agencies only Supplementary Table 1 . Continued 11. Are you aware of any action or education initiated by a patient organization in your country about biosimilars? 1) Yes, activities have started in IBD 2) Yes, activities have started in another specialty
3) Not aware of any action or education by a patient organization 12. A randomized clinical trial on rheumatoid arthritis showed no differences in efficacy and safety between the originator and a biosimilar mAb. You conclude:
1) The tested biosimilar mAb can be approved for all rheumatologic indications 2) All biosimilar mAb of the same originator can be approved for rheumatoid arthritis
3) The tested biosimilar mAb can be approved for all indications for which the originator is approved 4) All biosimilars of the same originator can be approved for all indications of the originator 5) None of the above 13. One randomized clinical trial on rheumatoid arthritis and one on ankylosing spondylitis showed no differences in efficacy and safety between the originator and a biosimilar mAb, with a 30% saving in costs. You conclude:
1) The tested biosimilar mAb should be the first choice for rheumatoid arthritis and ankylosing spondylitis
2) The tested biosimilar mAb should be the first choice for all indications as the originator
3) The originator and the tested biosimilar mAb should be first choices for the two indications Unneeded as biosimilars will be introduced into the system by regulators and payors anyway 0 (0.0) 1 (2.1) 0 (0.0) 1 (5.9)
Unneeded because biosimilars are at least as similar to their originator than separate batches of the originator have been during the last decade 4 (7.5) 4 (8. Values are presented as n (%). AOCC, Asian Organization of Crohn's and Colitis; TNF, tumor necrosis factor; mAb, monoclonal antibodies; INN, International Nonproprietary Names; IBD, inflammatory bowel diseases; RCT, randomized controlled trial; RA, rheumatoid arthritis; AS, ankylosing spondilitis; CD, Crohn's disease; UC, ulcerative colitis.
